literature

HIV mutation literature information.

Kinetics of CD4 cells after discontinuation of antiretroviral therapy in patients with virological failure and a CD4 cell count greater than 500 cells/microl.

PMID: 12131194 2002 AIDS (London, England)

Abstract: This decline was unrelated to the CD4 cell count and HIV-RNA values at interruption, but was more profound in patients in whom the M184V mutation had disappeared after lamivudine discontinuation.

Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).

PMID: 12131209 2002 AIDS (London, England)

Abstract: According to multivariate analysis, NFV Cmin and Cmax, CD4 cell count, number of baseline RT + protease gene mutations, D67N, M184V, T215F/Y in RT, and M36I in protease, were independent factors that were significantly predictive of failure.

Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.

PMID: 12163615 2002 Journal of virology

Abstract: Our results indicate that M184V impaired viral fitness in pair-wise comparisons of mutants that contained or lacked this substitution.

Abstract: Since the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase is associated with diminished fitness as well as lamivudine resistance, we introduced this substitution into several of our deletion mutants to determine its effects on viral replication and compensatory reversion.

Abstract: We also observed that M184V significantly impaired the potential for both compensatory mutagenesis and reversion in these mutants both in cell lines and in peripheral blood mononuclear cells.

Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.

PMID: 12172093 2002 AIDS (London, England)

Abstract: The number of thymidine analogue mutations (TAMs) was lower in isolates with M184V, this was independent of plasma HIV-1-RNA level and time on therapy for T215F/Y, D67N and L210W.

Abstract: The resistance of HIV clinical isolates with or without M184V was analysed in relation to plasma HIV-1-RNA level and time on therapy.

Abstract: This suggests a direct effect of M184V on the reduced selection of TAMs.

Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir.

PMID: 12176989 2002 The Journal of biological chemistry

Abstract: It was found that, similar to the multidrug-resistant mutant reverse transcriptase (RT)(Q151M), the mutations L74V, M184V, and a triple mutant containing L74V/Y115F/M184V all caused increased selectivity for dGTP over the active metabolite of abacavir (carbovir triphosphate).

Abstract: The triple mutant showed no advantage in selectivity over RT(M184V) and was severely impaired in its ability to remove a chain terminator, giving no kinetic basis for its increased resistance in a cellular system.

Exploring the effects of active site constraints on HIV-1 reverse transcriptase DNA polymerase fidelity.

PMID: 12200452 2002 The Journal of biological chemistry

Abstract: By increasing the steric demand the effects on RT(M184V) in comparison with RT(WT) become progressively more pronounced.

Abstract: Introduction of a methyl group reduces the maximum rate of nucleotide incorporation by about 200-fold for RT(WT) and about 400-fold for RT(M184V).

Abstract: This results in relative incorporation efficiencies [(k(pol)/K(d))(incorrect)/(k(pol)/K(d))(TTPcorrect)] of 4.1 x 10(-5) for TTP and 3.4 x 10(-6) for T(Me)TP in case of RT(WT) and 1.4 x 10(-5) for TTP and 2.9 x 10(-8) for T(Me)TP in case of RT(M184V).

Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215.

PMID: 12208978 2002 Journal of virology

Abstract: Six structures of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) containing combinations of resistance mutations for zidovudine (AZT) (M41L and T215Y) or lamivudine (M184V) have been determined as inhibitor complexes.

Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations.

PMID: 12218942 2002 Medical science monitor

Abstract: By contrast, mutations conferring resistance to reverse transcriptase inhibitors were present in 50% of the patients, and the M184V substitution was the most frequently seen.

Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance.

PMID: 12367719 2002 Antiviral research

Abstract: Mutations within immunogenic regions of clade C RT were noted during drug selection of subtype C isolates with nevirapine (S98I, Y181C, V108I and K103N), delavirdine, (A62V, V75E, L100I, K103T, V108I, Y181C), efavirenz (K103E, V106M, V179D, Y188C/H, G190A), lamivudine (M184I, M184V), and zidovudine (K70R), respectively.

Persistence of earlier HIV-1 drug resistance mutations at new treatment failure.

PMID: 12376953 2002 Journal of medical virology

Abstract: The M184V mutation disappeared in most (64%) non-3TC treated patients, although it persisted in a few didanosine- and abacavir-treated subjects.

Browser Board

Co-occurred Entities

Filtrator